臨床整形外科56巻10号

2021年10月発行

特集 脊椎転移の治療　最前線

脊椎転移診療における全身薬物療法の位置づけ

著者： 下井辰徳¹

所属機関： ¹国立がん研究センター中央病院腫瘍内科

ページ範囲：P.1239 - P.1248

　すべての悪性腫瘍症例の約10％が症候性脊椎転移を発症するとされるが，しばしば，骨転移に対しては初回治療として局所治療を優先するか，全身薬物療法から開始するかは議論のポイントとなる．近年のがん薬物療法の発展に伴い，がん種によっては8割以上の奏効割合が期待できる治療薬もあり，一方で，奏効に入るまでの期間は，治療内容によって1.5〜3カ月程度を要するものまでさまざまである．本稿では，骨転移を起こしやすい5つのがん種とその初回薬物療法の違いを概説し，がん種ごとの全身薬物療法の有効性を明確化することで，最適な脊椎転移治療を検討する一助としたい．

参考文献

1) Hosono N, Yonenobu K, Fuji T, et al. Orthopaedic management of spinal metastases. Clin Orthop Relat Res 1995;(312):148-59.

2) Kurisunkal V, Gulia A, Gupta S. Principles of management of spine metastasis. Indian J Orthop 2020;54:181-93.

3) Ziu E, Viswanathan VK, Mesfin FB. Spinal Metastasis. 2020 Aug 11. In:StatPearls [Internet]. Treasure Island (FL):StatPearls Publishing;2021 Jan.

4) Goldman JM, Ash CM, Souhami RL, et al. Spinal cord compression in small cell lung cancer:a retrospective sudy of 610 patients. Br J Cancer 1989;59(4):591-3.

5) Bilsky MH, Laufer I, Fourney DR, et al. Reliability analysis of the epidural spinal cord compression scale. J Neurosurg Spine 2010;13(3):324-8.

6) Hong S, Youk T, Lee SJ, et al. Bone metastasis and skeletal-related events in patients with solid cancer:a Korean nationwide health insurance database study. PLoS One 2020;15(7):e0234927.

7) Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29(9):1125-32.

8) Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016;375(20):1925-36.

9) Turner NC, Finn RS, Martin M, et al. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Ann Oncol 2018;29(3):669-80.

10) Rugo HS, Finn RS, Diéras V, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat 2019;174(3):719-29.

11) Baselga J, Cortés J, Kim SB, et al;CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366(2):109-19.

12) Swain SM, Baselga J, Kim SB, et al;CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015;372(8):724-34.

13) Swain SM, Miles D, Kim SB, et al;CLEOPATRA study group. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA):end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 2020;21(4):519-30.

14) Takahashi M, Ohtani S, Nagai SE, et al. The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer:the COMACHI study. Breast Cancer Res Treat 2021;185(1):125-34.

15) Schmid P, Adams S, Rugo HS, et al;IMpassion130 Trial Investigators. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018;379(22):2108-21.

点滴静注840mg(乳癌)(2020年12月改訂)．https://chugai-pharm.jp/content/dam/chugai/product/tec/div/guide-bc/doc/tec_guide_bc.pdf(2021年8月20日アクセス)

17) がんの統計編集委員会．がんの統計2019年版．公益財団法人がん研究振興財団2020．https://ganjoho.jp/data/reg_stat/statistics/brochure/2019/cancer_statistics_2019_fig_J.pdf(2021年7月25日アクセス)

18) Reck M, Rodríguez-Abreu D, Robinson AG, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50. J Clin Oncol 2021;39(21):2339-49.

19) Soria JC, Ohe Y, Vansteenkiste J, et al;FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378(2):113-25.

20) Ramalingam SS, Vansteenkiste J, Planchard D, et al;FLAURA Investigators. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 2020;382(1):41-50.

21) Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC):updated results, including overall survival, from PROFILE 1001. Ann Oncol 2019;30(7):1121-6.

22) Gadgeel S, Shaw AT, Barlesi F, et al. Time to response in patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) receiving alectinib in the Phase II NP28673 and NP28761 studies. Lung Cancer (Auckl) 2019;10:125-30.

23) Nakagawa K, Hida T, Nokihara H, et al. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer 2020;139:195-9.

24) Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 2019;381(21):2020-31.

25) Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX):an open-label, randomised phase 3 trial. Lancet 2017;390(10089):29-39.

26) Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer:an open-label, phase 2 trial. Lancet Oncol 2017;18(10):1307-16.

27) Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med 2020;383(9):813-24.

28) Kohno T, Nakaoku T, Tsuta K, et al. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res 2015;4(2):156-64.

29) 日本肺癌学会(編)．肺癌診療ガイドライン—悪性胸膜中皮腫・胸膜腫瘍含む 2020年版ver.1.1. 2021. https://www.haigan.gr.jp/modules/guideline/index.php?content_id=3(2021年8月20日アクセス)

30) Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15):a randomised, open-label, phase 3 trial. Lancet Oncol 2013;14(2):149-58.

31) Fizazi K, Tran N, Fein L, et al;LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377(4):352-60.

32) Fizazi K, Tran N, Fein L, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE):final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 2019;20(5):686-700.

33) Davis ID, Martin AJ, Stockler MR, et al;ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 2019;381(2):121-31.

34) Chi KN, Agarwal N, Bjartell A, et al;TITAN Investigators. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 2019;381(1):13-24.

35) Fizazi K, Maldonado X, Foulon S, et al. A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC):first results of PEACE-1. J Clin Oncol 2021;39(suppl 15:abstr 5000)

36) Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-20.

37) Tannock IF, de Wit R, Berry WR, et al;TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12.

38) Scher HI, Fizazi K, Saad F, et al;AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187-97.

39) Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES:a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2019;37(32):2974-86.

40) Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20(1):289-96.

41) Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents:results from a large, multicenter study. J Clin Oncol 2009;27(34):5794-9.

42) Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426):extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol 2020;21(12):1563-73.

43) Rini BI, Plimack ER, Stus V, et al;KEYNOTE-426 Investigators. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1116-27.

44) Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma:results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061-8.

45) Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584-90.

46) Molina AM, Lin X, Korytowsky B, et al. Sunitinib objective response in metastatic renal cell carcinoma:analysis of 1059 patients treated on clinical trials. Eur J Cancer 2014;50(2):351-8.

47) Motzer RJ, Tannir NM, McDermott DF, et al;CheckMate 214 Investigators. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378(14):1277-90.

48) Motzer RJ, Rini BI, McDermott DF, et al;CheckMate 214 investigators. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma:extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 2019;20(10):1370-85.

49) Lambertini M, Agbor-Tarh D, Metzger-Filho O, et al. Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer:analysis from the ALTTO (BIG 2-06) trial. ESMO Open 2020;5(6):e000979.

50) de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18(16):2938-47.

51) Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK:a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014;32(21):2240-7.

52) Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3):a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15(10):1065-75.

53) Stintzing S, Modest DP, Rossius L, et al;FIRE-3 investigators. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3):a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol 2016;17(10):1426-34.

54) Gruenberger T, Bridgewater J, Chau I, et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer:the OLIVIA multinational randomised phase II trial. Ann Oncol 2015;26(4):702-8.

55) Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer:updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015;16(13):1306-15.